Morse Asset Management, Inc Gilead Sciences, Inc. Transaction History

Morse Asset Management, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 05, 2019	SELL	$62.51 - $69.0 $1.1 Million - $1.22 Million	-17,655 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$61.87 - $69.38 $1.15 Million - $1.28 Million	-18,520 Reduced 51.2%	17,655 $1.19 Million
Q1 2019 May 02, 2019	SELL	$62.53 - $70.05 $715,968 - $802,072	-11,450 Reduced 24.04%	36,175 $2.35 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $112,604 - $146,940	-1,860 Reduced 3.76%	47,625 $2.98 Million
Q3 2018 Nov 01, 2018	BUY	$71.28 - $78.92 $352,836 - $390,654	4,950 Added 11.11%	49,485 $3.82 Million
Q2 2018 Aug 15, 2018	SELL	$64.88 - $75.68 $492,114 - $574,032	-7,585 Reduced 14.55%	44,535 $3.16 Million
Q1 2018 May 02, 2018	BUY	$72.84 - $88.8 $796,869 - $971,472	10,940 Added 26.57%	52,120 $3.93 Million
Q4 2017 Jan 29, 2018	BUY	$71.15 - $83.52 $147,992 - $173,721	2,080 Added 5.32%	41,180 $2.95 Million
Q3 2017 Oct 31, 2017	BUY	$72.11 - $85.47 $2.82 Million - $3.34 Million	39,100	39,100 $3.17 Million

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Morse Asset Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Morse Asset Management, Inc with notifications on news.